1. Key Insights

2. Report Introduction

3. AUD Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of AUD in 2019
3.2. Patient Share (%) Distribution of AUD in 2032

4. Executive Summary of AUD Epidemiology

5. Disease Background and Overview
5.1. Introduction to AUD
5.2. Definitions
5.3. Causes and risk factors
5.4. Subtypes of Alcoholics
5.5. Pathophysiology
5.5.1. Neuroimmune Activation in the Pathology of Alcoholism
5.6. Genetics of AUD
5.7. Diagnosis
5.8. Biomarkers

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Methodology of Epidemiology
6.3. Assumptions and Rationale: the 7MM
6.3.1. 12-month Diagnosed Prevalent Cases of AUD
6.3.2. Gender-specific Diagnosed Prevalent Cases of AUD
6.3.3. Type-specific cases of AUD
6.3.4. Treated Cases of AUD
6.4. Total 12-month Diagnosed Prevalent Cases of AUD in the 7MM
6.5. The US
6.5.1. 12-month Diagnosed Prevalent Cases of AUD in the US
6.5.2. Gender-specific Diagnosed Prevalent Cases of AUD in the US
6.5.3. Type-specific Diagnosed Prevalent Cases of AUD in the US
6.6. The Five European Countries
6.6.1. 12-month Diagnosed Prevalent Cases of AUD in the EU-5
6.6.2. Gender-specific Diagnosed Prevalent Cases of AUD in the EU-5
6.6.3. Type-specific Diagnosed Prevalent Cases of AUD in the EU-5
6.6.4. Germany
6.6.4.1. 12-month Diagnosed Prevalent Cases of AUD in Germany
6.6.4.2. Gender-specific Diagnosed Prevalent Cases of AUD in Germany
6.6.4.3. Type-specific Diagnosed Prevalent Cases of AUD in Germany
6.6.5. France
6.6.5.1. 12-month Diagnosed Prevalent Cases of AUD in France
6.6.5.2. Gender-specific Diagnosed Prevalent Cases of AUD in France
6.6.5.3. Type-specific Diagnosed Prevalent Cases of AUD in France
6.6.6. Italy
6.6.6.1. 12-month Diagnosed Prevalent Cases of AUD in Italy
6.6.6.2. Gender-specific Diagnosed Prevalent Cases of AUD in Italy
6.6.6.3. Type-specific Diagnosed Prevalent Cases of AUD in Italy
6.6.7. Spain
6.6.7.1. 12-month Diagnosed Prevalent Cases of AUD in Spain
6.6.7.2. Gender-specific Diagnosed Prevalent Cases of AUD in Spain
6.6.7.3. Type-specific Diagnosed Prevalent Cases of AUD in Spain
6.6.8. The UK
6.6.8.1. 12-month Diagnosed Prevalent Cases of AUD in the UK
6.6.8.2. Gender-specific Diagnosed Prevalent Cases of AUD in the UK
6.6.8.3. Type-specific Diagnosed Prevalent Cases of AUD in the UK
6.7. Japan
6.7.1. 12-month Diagnosed Prevalent Cases of AUD in Japan
6.7.2. Gender-specific Diagnosed Prevalent Cases of AUD in Japan
6.7.3. Type-specific Diagnosed Prevalent Cases of AUD in Japan

7. Patient Journey

8. Key Opinion Leaders' Views

9. Appendix
9.1. Bibliography
9.2. Acronyms and Abbreviations

10. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

List of Tables
Table 1: Summary of AUD Epidemiology (2019-2032)
Table 2: Total 12-month Diagnosed Prevalent Cases of AUD in the 7MM, in Thousands (2019-2032)
Table 3: 12-month Diagnosed Prevalent Cases of AUD in the US, in Thousands (2019-2032)
Table 4: Gender-specific Diagnosed Prevalent Cases of AUD in the US, in Thousands (2019-2032)
Table 5: Type-specific Diagnosed Prevalent Cases of AUD in the US, in Thousands (2019-2032)
Table 6: 12-month Diagnosed Prevalent Cases of AUD in the EU-5, in Thousands (2019-2032)
Table 7: Gender-specific Diagnosed Prevalent Cases of AUD in the EU-5, in Thousands (2019-2032)
Table 8: Type-specific Diagnosed Prevalent Cases of AUD in the EU-5, in Thousands (2019-2032)
Table 9: 12-month Diagnosed Prevalent Cases of AUD in Germany, in Thousands (2019-2032)
Table 10: Gender-specific Diagnosed Prevalent Cases of AUD in Germany, in Thousands (2019-2032)
Table 11: Type-specific Diagnosed Prevalent Cases of AUD in Germany, in Thousands (2019-2032)
Table 12: 12-month Diagnosed Prevalent Cases of AUD in France, in Thousands (2019-2032)
Table 13: Gender-specific Diagnosed Prevalent Cases of AUD in France, in Thousands (2019-2032)
Table 14: Type-specific Diagnosed Prevalent Cases of AUD in France, in Thousands (2019-2032)
Table 15: 12-month Diagnosed Prevalent Cases of AUD in Italy, in Thousands (2019-2032)
Table 16: Gender-specific Diagnosed Prevalent Cases of AUD in Italy, in Thousands (2019-2032)
Table 17: Type-specific Diagnosed Prevalent Cases of AUD in Italy, in Thousands (2019-2032)
Table 18: 12-month Diagnosed Prevalent Cases of AUD in Spain, in Thousands (2019-2032)
Table 19: Gender-specific Diagnosed Prevalent Cases of AUD in Spain, in Thousands (2019-2032)
Table 20: Type-specific Diagnosed Prevalent Cases of AUD in Spain, in Thousands (2019-2032)
Table 21: 12-month Diagnosed Prevalent Cases of AUD in the UK, in Thousands (2019-2032)
Table 22: Gender-specific Diagnosed Prevalent Cases of AUD in the UK, in Thousands (2019-2032)
Table 23: Type-specific Diagnosed Prevalent Cases of AUD in the UK, in Thousands (2019-2032)
Table 24: 12-month Diagnosed Prevalent Cases of AUD in Japan, in Thousands (2019-2032)
Table 25: Gender-specific Diagnosed Prevalent Cases of AUD in Japan, in Thousands (2019-2032)
Table 26: Type-specific Diagnosed Prevalent Cases of AUD in Japan, in Thousands (2019-2032)

List of Figures
Figure 1: Causes and risk factors
Figure 2: Natural history of alcohol use disorders
Figure 3: Neuroimmune contributions to the cycle of addiction
Figure 4: Neuron-glia cell-cell interactions in neuroimmune responses to alcohol
Figure 5: AUDIT-C questionnaire
Figure 6: Total 12-month Diagnosed Prevalent Cases of AUD in the 7MM (2019-2032)
Figure 7: 12-month Diagnosed Prevalent Cases of AUD in the US (2019-2032)
Figure 8: Gender-specific Diagnosed Prevalent Cases of AUD in the US (2019-2032)
Figure 9: Type-specific Diagnosed Prevalent Cases of AUD in the US (2019-2032)
Figure 10: 12-month Diagnosed Prevalent Cases of AUD in the EU-5 (2019-2032)
Figure 11: Gender-specific Diagnosed Prevalent Cases of AUD in the EU-5 (2019-2032)
Figure 12: Type-specific Diagnosed Prevalent Cases of AUD in the EU-5 (2019-2032)
Figure 13: 12-month Diagnosed Prevalent Cases of AUD in Germany (2019-2032)
Figure 14: Gender-specific Diagnosed Prevalent Cases of AUD in Germany (2019-2032)
Figure 15: Type-specific Diagnosed Prevalent Cases of AUD in Germany (2019-2032)
Figure 16: 12-month Diagnosed Prevalent Cases of AUD in France (2019-2032)
Figure 17: Gender-specific Diagnosed Prevalent Cases of AUD in France (2019-2032)
Figure 18: Type-specific Diagnosed Prevalent Cases of AUD in France (2019-2032)
Figure 19: 12-month Diagnosed Prevalent Cases of AUD in Italy (2019-2032)
Figure 20: Gender-specific Diagnosed Prevalent Cases of AUD in Italy (2019-2032)
Figure 21: Type-specific Diagnosed Prevalent Cases of AUD in Italy (2019-2032)
Figure 22: 12-month Diagnosed Prevalent Cases of AUD in Spain (2019-2032)
Figure 23: Gender-specific Diagnosed Prevalent Cases of AUD in Spain (2019-2032)
Figure 24: Type-specific Diagnosed Prevalent Cases of AUD in Spain (2019-2032)
Figure 25: 12-month Diagnosed Prevalent Cases of AUD in the UK (2019-2032)
Figure 26: Gender-specific Diagnosed Prevalent Cases of AUD in the UK (2019-2032)
Figure 27: Type-specific Diagnosed Prevalent Cases of AUD in the UK (2019-2032)
Figure 28: 12-month Diagnosed Prevalent Cases of AUD in Japan (2019-2032)
Figure 29: Gender-specific Diagnosed Prevalent Cases of AUD in Japan (2019-2032)
Figure 30: Type-specific Diagnosed Prevalent Cases of AUD in Japan (2019-2032)
Figure 31: Patient Journey